Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.79 |
| ▸ | KIT | P10721 | 17/20 | 0.79 |
| ▸ | FLT3 | P36888 | 17/20 | 0.79 |
| ▸ | CSF1R | P07333 | 6/20 | 0.79 |
| ▸ | FLT1 | P17948 | 6/20 | 0.79 |
| ▸ | FLT4 | P35916 | 6/20 | 0.79 |
| ▸ | LCK | P06239 | 5/20 | 0.79 |
| ▸ | PLK4 | O00444 | 3/20 | 0.79 |
| ▸ | AURKA | O14965 | 3/20 | 0.79 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.79 |
| ▸ | INSR | P06213 | 3/20 | 0.79 |
| ▸ | MET | P08581 | 3/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.79 |
| ▸ | PRKACA | P17612 | 3/20 | 0.79 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.79 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.79 |
| ▸ | STK3 | Q13188 | 3/20 | 0.79 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.79 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.79 |
| ▸ | MARK2 | Q7KZI7 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419365 | 0.89 | KDR (1.00) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL423365 | 0.87 | KDR (1.00) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL421644 | 0.84 | KDR (1.00) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL16475318 | 0.82 | KDR (0.80) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL419770 | 0.82 | KDR (0.74) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL421458 | 0.82 | KDR (1.00) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL423038 | 0.82 | KDR (1.00) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL423713 | 0.82 | KDR (0.78) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL13857841 | 0.82 | KDR (0.76) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL24232942 | 0.82 | KDR (0.82) | KDRKITFLT3CSF1RFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004245-A1 | COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES | ALCON RESEARCH, LTD. (US) | 2012-01-05 | — | — | US | claimed |
| US-20120004245-A1 | COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES | ALCON RESEARCH, LTD. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004245-A1 | COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES | ALCON RESEARCH, LTD. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004245-A1 | COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES | ALCON RESEARCH, LTD. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2012003141-A1 | COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES | ALCON RESEARCH, LTD. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004245-A1 | COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES | ALDH1A2, UACA, VHL | KDR 210/4885KIT 2839/4885FLT3 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.